Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025

Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors,...

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025

Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non‑exclusive licensing agreement with EirGenix...

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...

Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025

Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy,...

Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025

China’s National Medical Products Administration (NMPA) published the 2025 Edition of the Directory of High-End...

Company Medical Device

Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU

Fineline Cube Dec 29, 2025

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that it has submitted the registration application for...

Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025

TJ Biopharma announced a strategic cooperation agreement with Zhejiang Lab Technology Holdings Co., Ltd. (Zhike...

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQH3906, a Category 1 innovative oral TYK2/JAK1 inhibitor, has...

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025

HBM Holdings Limited (HKG: 2142) announced a long‑term strategic collaboration with Yantai Lannacheng Biotechnology Co.,...

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025

Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience...

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025

AstraZeneca PLC (AZ, NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) announced that Wainua (eplontersen) has received approval...

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025

AstraZeneca PLC (AZ, NASDAQ: AZN) announced that Fasenra (benralizumab) has received additional approval from China’s...

Company Drug

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

Fineline Cube Dec 29, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Medical Device

Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China

Fineline Cube Dec 29, 2025

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its Human Immunodeficiency Virus...

Company Drug

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Fineline Cube Dec 29, 2025

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that furmonertinib has been added to the Breakthrough...

Company Medical Device

UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio

Fineline Cube Dec 29, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG: 2252) announced that its self‑developed UniPath Electronic Bronchoscopic...

Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Fineline Cube Dec 29, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that China’s National Medical Products Administration (NMPA) accepted...

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Fineline Cube Dec 29, 2025

Novo Nordisk (NYSE: NVO) announced that its once‑weekly long‑acting growth hormone (LAGH) injection, Sogroya (somapacitan), received...

Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Fineline Cube Dec 29, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Amivantamab Injection (Subcutaneous), marketed as RYBREVANT, received...

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025

Hybio Pharmaceutical and Dr. Reddy’s Laboratories entered a strategic partnership, signing a non‑binding Term Sheet...

Posts pagination

1 … 41 42 43 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.